*  Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients | MD Anderson Cancer Center
Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients. MD Anderson News Release 05/31/2011 ... A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better ... extending disease-free survival time from 28.7 months to 52.9 months. While those results need to be confirmed in randomized ... "Survival of follicular lymphoma patients has improved with newer types of chemotherapy, but advanced-stage disease still is ...
  https://www.mdanderson.org/newsroom/2011/05/vaccine-increases-disease-free-survival-for-follicular-lymphoma-.html
*  Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer - The ASCO Post
Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer. By Chase Doyle and Caroline Helwick. ... "ExteNET is the first study to show a statistically significant improvement in invasive disease-free survival in the intent-to- ... ExteNet's primary analysis was the invasive disease-free survival for all patients treated who had completed 2 years of follow- ... 2. Chan A, Martin M, Von Minckwitz G, et al: Invasive disease-free survival benefit following neratinib as extended adjuvant ...
  http://www.ascopost.com/issues/november-25-2015/neratinib-improves-disease-free-survival-in-early-stage-her2-positive-breast-cancer/
*  Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer - The ASCO Post
... with significantly poorer disease-free survival observed for current vs never-smokers with BRAF wild-type disease (HR = 1.60, ... there was evidence of poorer disease-free survival for smokers vs nonsmokers with KRAS mutant disease. Among patients with KRAS ... Disease-free Survival in Ever-smokers. Median follow up in patients not experiencing events was 3.5 years. On unadjusted ... However, disease-free survival was significantly poorer for ever-smokers vs never-smokers who were male (HR = 1.33, 95% CI = ...
  http://www.ascopost.com/issues/june-10-2013/smoking-linked-to-shorter-disease-free-survival-in-stage-iii-colon-cancer/
*  Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem...
S. G. Holtan, T. E. DeFor, A. Lazaryan et al., "Composite end point of graft-versus-host disease-free, relapse-free survival ... Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem ... A. Jalali, K. Alimoghaddam, M. Mahmoudi et al., "The EBMT risk score in the presence of graft versus host disease in allogeneic ... P. Ljungman, M. Hakki, and M. Boeckh, "Cytomegalovirus in hematopoietic stem cell transplant recipients," Infectious Disease ...
  https://www.hindawi.com/journals/sci/2016/5143071/ref/
*  Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing...
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast ... Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing ... to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival. ... Breast Diseases. Skin Diseases. Paclitaxel. Docetaxel. Liposomal doxorubicin. Albumin-Bound Paclitaxel. Cyclophosphamide. ...
  https://clinicaltrials.gov/ct2/show/NCT01779050
*  Renal-Cell Cancer Disease-Free Survival Up With Sunitinib | Physician's Weekly for Medical News, Journals & Articles
Renal-Cell Cancer Disease-Free Survival Up With Sunitinib by Logan Thomison , Oct 11, 2016 , 0 comments ... The researchers found that the median duration of disease-free survival was 6.8 and 5.6 years in the sunitinib and placebo ... 11, 2016 (HealthDay News) - The duration of disease-free survival is increased with sunitinib treatment for patients with ... the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a ...
  https://www.physiciansweekly.com/renal-cell-cancer-disease-free-survival-up-with-sunitinib/
*  Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma | Clinical...
Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma. Ernest Nadal ... Patients with increased miR-34b/c methylation had significantly shorter disease-free and overall survival as compared to ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ...
  http://clincancerres.aacrjournals.org/content/early/2013/12/12/1078-0432.CCR-13-0736
*  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897...
... and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob ... Adjuvant chemotherapy for early stage breast cancer patients has greatly improved both disease-free and overall survival by ... Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest ... Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial ...
  http://clincancerres.aacrjournals.org/content/16/24/6169.long
*  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free...
... and reduced disease-free survival (P , 0.05).. Conclusions: IGF2 modulates Taxol resistance, and tumor IGF2 expression is a ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ...
  http://clincancerres.aacrjournals.org/content/early/2010/05/13/1078-0432.CCR-09-3233
*  A) Disease-free survival and overall survival for pati | Open-i
A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH) or ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Disease-free survival and overall survival for patients with early-stage cervical cancer undergoing TLRH or ARH, and with ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4554128_medi-94-e1264-g005&req=4
*  Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival | Breast Cancer Research | Full Text
Postoperative radiotherapyPreoperative radiotherapyEarly-stage breast cancerOverall survivalDisease-free survivalImmune ... Neoadjuvant RT may significantly improve disease-free survival without reducing overall survival, especially for estrogen ... improves relapse-free survival of patients with early-stage breast cancer. We evaluated the long-term overall and disease-free ... Disease-free survival, defined as time to diagnosis of a second primary tumor at any location, was calculated from automated ...
  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-017-0870-1
*  Tumor Diameter for Prediction of Recurrence, Disease Free and Overall Survival in Endometrial Cancer Cases | Korea Science
Disease Free and Overall Survival in Endometrial Cancer Cases - Endometrial cancer;tumor diameter;overall survival;disease free ... Aims: To analyse the predictors of recurrence, disease free survival and overall survival in cases with endometrial cancer. ... disease free survival and overall survival. Results: In ROC analyses tumor diameter was a significant predictor of recurrence ( ... Tumor Diameter for Prediction of Recurrence, Disease Free and Overall Survival in Endometrial Cancer Cases. Senol, Taylan; ...
  http://www.koreascience.or.kr/article/ArticleFullRecord.jsp?cn=POCPA9_2015_v16n17_7463
*  Zoledronic Acid Did Not Improve Disease Free Survival in Early Breast Cancer | AACR News
Zoledronic acid did not improve disease free survival among women with stage II/III breast cancer according to results of the ... The primary outcome was disease free survival.. The researchers found no difference in disease free survival in the overall ... SAN ANTONIO - Zoledronic acid did not improve disease free survival among women with stage II/III breast cancer according to ... Zoledronic Acid Did Not Improve Disease Free Survival in Early Breast Cancer. December 9, 2010 ...
  https://aacrnews.wordpress.com/2010/12/09/zoledronic-acid-did-not-improve-disease-free-survival-in-early-breast-cancer/
*  Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in...
Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in ...
  http://vivo.med.cornell.edu/display/pubid84944907528
*  Overall survival (OAS) and disease-free survival (DFS) | Open-i
... and disease-free survival (DFS) for TNBC patients who received 100% guideline-adherent adjuvant treatment, as stratified by age ... 74.6%)]. In TNBC patients of all age groups, disease-free survival and overall survival were associated with an improvement by ... 74.6%)]. In TNBC patients of all age groups, disease-free survival and overall survival were associated with an improvement by ... Figure 5: Overall survival (OAS) and disease-free survival (DFS) for TNBC patients who received 100% guideline-adherent ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC3815231_1471-2407-13-487-5&req=4
*  A) Overall survival, disease-free survival, and loco-r | Open-i
... disease-free survival, and loco-regional control rates after definitive radiotherapy for vaginal cancer. (B, C) Overall ... B, C) Overall survival and disease-free survival rates according to FIGO stage. Mentions: At the time of analysis, the median ... RRU115F1: (A) Overall survival, disease-free survival, and loco-regional control rates after definitive radiotherapy for ... RRU115F1: (A) Overall survival, disease-free survival, and loco-regional control rates after definitive radiotherapy for ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4380060_rru11501&req=4
*  Disease-free survival curve (A) and overall survival cu | Open-i
... and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A ... Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s ... Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s ... Conclusions: High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44s- ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC3140667_gnl-5-204-g002&req=4
*  Sunitinib increases disease free survival in high risk renal carcinoma post nephrectomy | 2 Minute Medicine | AccessMedicine |...
The primary endpoint was disease-free survival, and secondary endpoints were overall survival and safety. ... "Sunitinib increases disease free survival in high risk renal carcinoma post nephrectomy." 2 Minute Medicine New York, NY: ... The median disease free survival was 6.8 years (95%CI 5.8-not reached) in the sunitinib group, and 5.6 years (95%CI 3.6-6.6) in ... D'Souza N, Deghan S. D'Souza N, Deghan S D'Souza, Neil, and Shaidah Deghan. "Sunitinib increases disease free survival in high ...
  http://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=324384§ionid=147951215&categoryid=41164
*  Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in localized...
Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in localized ... 9PD - Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in ... Analyzing initial biopsies, survival outcome for high- vs low-TILs pts was not different (LPFS: HR 1.07; n.s.; DFS: HR 1.14, n. ... ESMO Consensus Conferences discuss key questions in certain disease areas and complement the ESMO Clinical Practice Guidelines ...
  http://oncologypro.esmo.org/Meeting-Resources/Immuno-Oncology-2015/Impact-of-tumor-infiltrating-lymphocytes-TILs-on-local-progression-free-LPFS-and-disease-free-DFS-survival-in-localized-high-risk-soft-tissue-sarcoma-HR-STS-after-neo-adjuvant-chemotherapy-NAC-with-regional-hyperthermia-RHT
*  HPV Status Linked to Overall and Disease-free Survival in Vulvar Cancer - Cancer Therapy Advisor
Seven studies investigated the effect of HPV status on 5-year disease free survival (DFS) and showed a pooled HR of 0.75 (95% ... HPV Status Linked to Overall and Disease-free Survival in Vulvar Cancer. Share this content: *facebook ... HPV Status Linked to Overall and Disease-free Survival in Vulvar Cancer ... Does HPV status influence survival after vulvar cancer? Inter J Canc. 2017 Nov 1. doi: 10.1002/ijc.31139 [Epub ahead of print] ...
  https://www.cancertherapyadvisor.com/gynecologic-cancer/vulvar-cancer-hpv-status-overall-diease-free-survival-link/article/704705/
*  Penny PayDay: Galena Bio (Nasdaq: GALE) NeuVax Phase 1/2 boosters improve disease-free survival at 60 month
The results show that, at a median of 60-months, the disease-free survival (DFS) for the booster group (n=53) was 96.2% vs 80.5 ... Galena Bio (Nasdaq: GALE) NeuVax Phase 1/2 boosters improve disease-free survival at 60 month ...
  http://penny-payday.blogspot.com/2012/06/galena-bio-nasdaq-gale-neuvax-phase-12.html
*  "Local control and disease-free survival after treatment of a squamous " by H D. Suit, R Sedlacek et al.
Local control and disease-free survival after treatment of a squamous cell carcinoma by corynebacterium parvum and local ... Suit, H D.; Sedlacek, R; and Silobrcic, V, "Local control and disease-free survival after treatment of a squamous cell ...
  https://mouseion.jax.org/ssbb1977/207/
*  Synchronous hepatic metastasis and metachronous Krukenberg tumor from advanced colon cancer. A case report with an unexpected...
... in the literature there do not appear to be cases of such disease-free survival. The survival of patient despite the prognostic ... is disease-free 13 years after surgery.DiscussionTo our knowledge, ... BackgroundIn the international literature we have never found a long survival in patients treated for a colon cancer with ... for the treatment of the microscopic peritoneal neoplastic remnant.ConclusionThe authors emphasize that the long term survival ...
  https://www.iris.unict.it/handle/20.500.11769/40839
*  Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative...
DFS disease-free survival. In different subclinical groups, the relationship between ATG5 rs473543 genotypes and DFS was ... Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative ... Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast ... Autophagy-related gene 5Triple-negative breast cancerDisease-free survivalAnthracyclineTaxanes ...
  https://cjcjournal.biomedcentral.com/articles/10.1186/s40880-018-0268-1
*  Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease...
Progression-Free,Survival,and,Disease,Control,in,Metastatic,Colorectal,Cancer,Patients,medicine,advanced medical technology, ... The improvement in progression-free survival and response rateexpand...As previously reported the study's primary endpoint of ... Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease, ... Patients who received irinotecan alone experienced median overall survival of 9.99 months and median progression-free survival ...
  http://www.bio-medicine.org/medicine-technology/Randomized-Phase-III-Trial-Showed-Erbitux-Significantly-Improved-0ASecondary-Endpoints-of-Progression-Free-Survival-and-Disease-0AControl-in-Metastati-980-1/